Although the number of AGR2‐positive cases was low (7.8%) in this cancer entity, AGR2 expression analysis might become clinically useful in this cancer type because patients with high‐risk renal cell carcinomas are increasingly subjected to adjuvant chemotherapy, and risk assessment by histology alone is not sufficient for a safe individual risk assessment. The gene discussed is AGR2; the disease is cancer.